electroCore Receives FDA Breakthrough Device Designation

According to the last report, electroCore had provided an important update that acquired the designation of a breakthrough device from the U.S. Food and Drug Administration (FDA) to treat Posttraumatic Stress Disorder (PTSD)—in short, showing a 31% decrease in PTSD symptoms compared to sham on the gammaCore™ NVNC device. After this news from the FDA, electroCore’s stock price enormously boomed, marking an increase of over 36%. In detail, the worth yesterday was closed at $ 0.5351, and now it is open at $ 0.7370.


Hence, posttraumatic stress disorder (PTSD) is a condition that affects some people who have been through a stressful, fearful, or unsafe incident. It’s normal to be scared during and after a terrible event. In this case, PTSD is a common and disabling disorder with limited approved treatment options. And the gammaCore™ nVNS device demonstrated a decrease in PTSD symptoms by as much as 31%, as I earlier noted. According to data, about 15 million adults have PTSD every year. The ultimate goal of the Breakthrough Devices program is to provide patients and healthcare providers with timely access quickly and efficiently while maintaining the law.